Kyle Mikson
Stock Analyst at Canaccord Genuity
(1.04)
# 3,723
Out of 4,944 analysts
86
Total ratings
27.14%
Success rate
-11.05%
Average return
Main Sectors:
Stocks Rated by Kyle Mikson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QTRX Quanterix | Downgrades: Hold | $12 → $5 | $4.94 | +1.21% | 7 | Aug 11, 2025 | |
| ILMN Illumina | Maintains: Hold | $99 → $105 | $100.07 | +4.93% | 12 | Aug 1, 2025 | |
| XGN Exagen | Maintains: Buy | $8 → $11 | $9.63 | +14.29% | 4 | Jul 30, 2025 | |
| GRAL GRAIL | Maintains: Buy | $32 → $43 | $33.84 | +27.07% | 2 | May 14, 2025 | |
| BDSX Biodesix | Maintains: Buy | $2.5 → $1.5 | $0.41 | +262.49% | 4 | May 14, 2025 | |
| TXG 10x Genomics | Maintains: Buy | $18 → $15 | $13.58 | +10.46% | 8 | May 12, 2025 | |
| CSTL Castle Biosciences | Maintains: Buy | $42 → $37 | $19.48 | +89.99% | 4 | May 6, 2025 | |
| GH Guardant Health | Maintains: Buy | $60 → $65 | $56.35 | +15.35% | 7 | May 1, 2025 | |
| RGEN Repligen | Maintains: Hold | $170 → $150 | $122.64 | +22.31% | 3 | Apr 16, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Buy | $3 | $1.31 | +129.89% | 8 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $195 | $156.63 | +24.50% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 | $0.99 | +201.84% | 4 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $1.5 → $1 | $1.17 | -14.16% | 3 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $95 → $75 | $43.66 | +71.80% | 9 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $2 | $0.62 | +222.58% | 2 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $49 | $0.46 | +10,595.65% | 1 | Mar 30, 2021 |
Quanterix
Aug 11, 2025
Downgrades: Hold
Price Target: $12 → $5
Current: $4.94
Upside: +1.21%
Illumina
Aug 1, 2025
Maintains: Hold
Price Target: $99 → $105
Current: $100.07
Upside: +4.93%
Exagen
Jul 30, 2025
Maintains: Buy
Price Target: $8 → $11
Current: $9.63
Upside: +14.29%
GRAIL
May 14, 2025
Maintains: Buy
Price Target: $32 → $43
Current: $33.84
Upside: +27.07%
Biodesix
May 14, 2025
Maintains: Buy
Price Target: $2.5 → $1.5
Current: $0.41
Upside: +262.49%
10x Genomics
May 12, 2025
Maintains: Buy
Price Target: $18 → $15
Current: $13.58
Upside: +10.46%
Castle Biosciences
May 6, 2025
Maintains: Buy
Price Target: $42 → $37
Current: $19.48
Upside: +89.99%
Guardant Health
May 1, 2025
Maintains: Buy
Price Target: $60 → $65
Current: $56.35
Upside: +15.35%
Repligen
Apr 16, 2025
Maintains: Hold
Price Target: $170 → $150
Current: $122.64
Upside: +22.31%
Pacific Biosciences of California
Apr 10, 2025
Maintains: Buy
Price Target: $3
Current: $1.31
Upside: +129.89%
Feb 28, 2025
Maintains: Buy
Price Target: $180 → $195
Current: $156.63
Upside: +24.50%
Nov 14, 2024
Maintains: Buy
Price Target: $3
Current: $0.99
Upside: +201.84%
Nov 13, 2024
Maintains: Hold
Price Target: $1.5 → $1
Current: $1.17
Upside: -14.16%
Nov 6, 2024
Maintains: Buy
Price Target: $95 → $75
Current: $43.66
Upside: +71.80%
Aug 16, 2023
Maintains: Overweight
Price Target: $3 → $2
Current: $0.62
Upside: +222.58%
Mar 30, 2021
Initiates: Overweight
Price Target: $49
Current: $0.46
Upside: +10,595.65%